New analysis suggests breast cancer screening overdiagnosis risk is below five percent

Study examines eight major trials

Scientists reviewed data from all eight major randomized screening trials to update previous estimates. They adjusted their calculations for variations in follow-up duration, how often women were screened, and testing that occurred after the trials finished. This comprehensive approach yielded results consistent with an overdiagnosis rate under 5%.

Previous high estimates face challenge

Earlier studies had suggested that between 30% and 50% of detected cancers might be overdiagnosed cases. Those higher figures have long shaped international debates regarding the benefits and harms of population-based screening programs. The new findings contradict those widely cited percentages by showing a much lower risk.

Overdiagnosis defined as harmless detection

The phenomenon involves identifying cancers that would never have caused symptoms or threatened health during a woman's lifetime. This issue has been considered a significant potential drawback of screening for many years. The debate over how often this occurs has now shifted based on the latest evidence.